Synergy in tumor suppression by direct interaction of Neutral Endopeptidase with PTEN

Cancer Cell

Volumn 5, Issue 1, 2004, Pages 67-78

  Sumitomo, Makoto ^a,b   Iwase, Akira ^a,c   Zheng, Rong ^a   Navarro, Daniel ^a   Kaminetzky, David ^a   Shen, Ruoqian ^a   Georgescu, Maria Magdalena ^d   Nanus, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEINASE;

ARTICLE; CANCER INHIBITION; CELL MEMBRANE; CHEMICAL INTERACTION; CONTROLLED STUDY; ELECTRICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STABILITY; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

EID: 1642512636     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00331-3     Document Type: Article

References (47)

1. Bunn P.A. Jr., Helfrich B.A., Brenner D.G., Chan D.C., Dykes D.J., Cohen A.J., Miller Y.E. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin. Cancer Res. 4:1998;2849-2858.
2. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., Sidransky D. Frequent inactivation of PTEN/ MMAC1 in primary prostate cancer. Cancer Res. 57:1997;4997-5000.
3. Cantley L.C., Neel B.G. New insights into tumor suppression. PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc. Natl. Acad. Sci. USA. 96:1999;4240-4245.
4. Caselli A., Mazzinghi B., Camici G., Manao G., Ramponi G. Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1. Biochem. Biophys. Res. Commun. 296:2002;692-697.
5. Chu P., Arber D.A. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am. J. Clin. Pathol. 113:2000;374-382.
6. Cohen A.J., Bunn P.A., Franklin W., Magill-Solc C., Hartmann C., Helfrich B., Gilman L., Folkvord J., Helm K., Miller Y.E. Neutral endopeptidase. variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux Cancer Res. 56:1996;831-839.
7. Dai J., Shen R., Sumitomo M., Goldberg J.S., Geng Y., Navarro D., Xu S., Koutcher J.A., Garzotto M., Powell C.T., Nanus D.M. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin. Cancer Res. 7:2001;1370-1377.
8. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:2001;822-826.
9. Freedland S.J., Seligson D.B., Liu A.Y., Pantuck A.J., Paik S.H., Horvath S., Wieder J.A., Zisman A., Nguyen D., Tso C.L.et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 55:2003;71-80.
10. Ganju R.K., Shpektor R.G., Brenner D.G., Shipp M.A. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood. 88:1996;4159-4165.
11. Georgescu M.M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl. Acad. Sci. USA. 96:1999;10182-10187.
12. Georgescu M.M., Kirsch K.H., Kaloudis P., Yang H., Pavletich N.P., Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res. 60:2000;7033-7038.
13. Gschwend J.E., Fair W.R., Powell C.T. Evaluation of the tetracycline-repressible transactivator system for inducible gene expression in human prostate cancer cell lines. Prostate. 33:1997;166-176.
14. Haas-Kogan D., Shalev N., Wong M., Mills G., Yount G., Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8:1998;1195-1198.
15. Hansson J., Abrahamsson P. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann. Oncol. 12(Suppl 2):2001;S145-S152.
16. Hill M.M., Hemmings B.A. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol. Ther. 93:2002;243-251.
17. Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., Tavtigian S.V., Bartel P.L., Adey N.B. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res. 60:2000;35-37.
18. Kenny J. Endopeptidase-24.11. putative substrates and possible roles Biochem. Soc. Trans. 21:1993;663-668.
19. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., Dixon J.E., Pandolfi P., Pavletich N.P. Crystal structure of the PTEN tumor suppressor. implications for its phosphoinositide phosphatase activity and membrane association Cell. 99:1999;323-334.
20. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R.et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
21. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:1998;13375-13378.
22. Maehama T., Taylor G.S., Dixon J.E. PTEN and myotubularin. novel phosphoinositide phosphatases Annu. Rev. Biochem. 70:2001;247-279.
23. Miller S.J., Lou D.Y., Seldin D.C., Lane W.S., Neel B.G. Direct identification of PTEN phosphorylation sites. FEBS Lett. 528:2002;145-153.
24. Nanus D.M., Papandreou C.N., Albino A.P. Expression of cell-surface peptidases in neoplastic cells. Kenny J., Boustead C.M. Cell-Surface Peptidases in Health and Disease. 1997;353-369 BIOS Scientific Publishers, Oxford.
25. Nelson J.B., Carducci M.A. Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Invest. 18:2000;87-96.
26. Papandreou C.N., Usmani B., Geng Y., Bogenrieder T., Freeman R., Wilk S., Finstad C.L., Reuter V.E., Powell C.T., Scheinberg D.et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med. 4:1998;50-57.
27. Pinna L.A. Protein kinase CK2. Int. J. Biochem. Cell Biol. 29:1997;551-554.
28. Riemann D., Hansen G.H., Niels-Christiansen L., Thorsen E., Immerdal L., Santos A.N., Kehlen A., Langner J., Danielsen E.M. Caveolae/lipid rafts in fibroblast-like synoviocytes. ectopeptidase-rich membrane microdomains Biochem. J. 354:2001;47-55.
29. Ronco P., Pollard H., Galceran M., Delauche M., Schwartz J.C., Verroust P. Distribution of enkephalinase (membrane metalloendopeptidase, E.C. 3.4.24.11) in rat organs. Detection using a monoclonal antibody. Lab. Invest. 58:1988;210-217.
30. Rozengurt E. Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. J. Cell. Physiol. 177:1998;507-517.
31. Shipp M.A., Look A.T. Hematopoietic differentiation antigens that are membrane-associated enzymes. cutting is the key! Blood. 82:1993;1052-1070.
32. Shipp M.A., Tarr G.E., Chen C.Y., Switzer S.N., Hersh L.B., Stein H., Sunday M.E., Reinherz E.L. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. USA. 88:1991;10662-10666.
33. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
34. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T.et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
35. Sumitomo M., Shen R., Walburg M., Dai J., Geng Y., Navarro D., Boileau G., Papandreou C.N., Giancotti F.G., Knudsen B., Nanus D.M. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J. Clin. Invest. 106:2000;1399-1407.
36. Sumitomo M., Milowsky M.I., Shen R., Navarro D., Dai J., Asano T., Hayakawa M., Nanus D.M. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res. 61:2001;3294-3298.
37. Tahir S.A., Yang G., Ebara S., Timme T.L., Satoh T., Li L., Goltsov A., Ittmann M., Morrisett J.D., Thompson T.C. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61:2001;3882-3885.
38. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., Li J., Parsons R., Ellenson L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57:1997;3935-3940.
39. Tolkacheva T., Boddapati M., Sanfiz A., Tsuchida K., Kimmelman A.C., Chan A.M. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 61:2001;4985-4989.
40. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276:2001;993-998.
41. Turner A.J., Isaac R.E., Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases. genomics and function Bioessays. 23:2001;261-269.
42. Vazquez F., Ramaswamy S., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 20:2000;5010-5018.
43. Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276:2001;48627-48630.
44. Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.J., Wood J., Ross C., Sawyers C.L., Whang Y.E. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl. Acad. Sci. USA. 97:2000;4233-4238. a.
45. Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J. Biol. Chem. 275:2000;21477-21485. b.
46. Yokomizo A., Tindall D.J., Drabkin H., Gemmill R., Franklin W., Yang P., Sugio K., Smith D.I., Liu W. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene. 17:1998;475-479.
47. Zhuang L., Lin J., Lu M.L., Solomon K.R., Freeman M.R. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 62:2002;2227-2231.